- |||||||||| prizloncabtagene autoleucel (JNJ-4496) / J&J
P1 data, Journal: A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. (Pubmed Central) - Apr 3, 2025 P1 Patients with CD19 and/or CD20-positive R/R B-NHL received a 3-day lymphodepletion (cyclophosphamide: 300 mg/m2 per day; fludarabine: 30 mg/m2 per day) followed by an IV dose of prizlon-cel...Prizlon-cel showed a favorable safety profile and a high and durable response in patients with r/r B-NHL, suggesting a promising treatment option for patients with r/r B-NHL. (ClinicalTrials.gov number: NCT04317885, NCT04655677, NCT04696432, NCT04693676).
- |||||||||| XB.2.2 / AbelZeta Pharma
Journal, IO biomarker: LIN28 upregulation in primary human T cells impaired CAR T antitumoral activity. (Pubmed Central) - Oct 31, 2024 LIN28 overexpression maintained human T cell phenotype markers and functionality but impaired the antitumoral cytotoxicity of NKG2D-CAR T cells both in vitro and in vivo. These findings highlight the intricate relationship between LIN28/let-7 axis and human T cell functionality, including in CAR T cell therapy.
- |||||||||| Epidaza (chidamide) / Chipscreen, AiRuiKa (camrelizumab) / HLB Bio Group, CART-30 / AbelZeta Pharma
Biomarker, Journal, Tumor microenvironment: Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma. (Pubmed Central) - Aug 2, 2024 P2 In this study, we evaluated the efficacy and safety of a triplet regimen consisting of the histone deacetylase inhibitor chidamide, decitabine and anti-PD-1 camrelizumab (CDP) in 52 patients with relapsed/refractory cHL who had previously received DP therapy (NCT04233294)...The classical CD30+ HRS-like cells interacted with the abundant immunosuppressive IL21+CD4+ T helper cells, forming a positive feedback loop that supported their survival...CDP treatment promoted the activation of diverse tumor-reactive CD8+ T cells and suppressed the proliferation of IL21+CD4+ T cells by inhibiting STAT1/3 signaling, thereby alleviating their immunosuppressive effects. These findings provide insights into the cHL microenvironment that contributes to anti-PD-1 resistance and highlight the therapeutic effectiveness of dual epi-immunotherapy in overcoming immunotherapy resistance.
- |||||||||| human adipose derived mesenchymal progenitor cell therapy / Cellular Biomedicine, ReJoin (human adipose-derived mesenchymal progenitor cells) / Cellular Biomedicine, AlloJoin (allogeneic human adipose-derived mesenchymal stem cell therapy) / Cellular Biomedicine
Trial completion date, Trial suspension, Trial primary completion date, Gram negative: A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection (clinicaltrials.gov) - Jul 22, 2024 P1/2, N=60, Suspended, These findings provide insights into the cHL microenvironment that contributes to anti-PD-1 resistance and highlight the therapeutic effectiveness of dual epi-immunotherapy in overcoming immunotherapy resistance. Trial completion date: Jul 2023 --> Mar 2025 | Recruiting --> Suspended | Trial primary completion date: May 2023 --> Dec 2024
- |||||||||| C-TIL051 / AbelZeta Pharma
Enrollment open, Metastases: C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Mar 1, 2024 P1, N=20, Recruiting, Trial completion date: Oct 2027 --> Oct 2028 Not yet recruiting --> Recruiting
- |||||||||| C-TIL051 / AbelZeta Pharma
Trial completion date, Trial primary completion date, Metastases: C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 31, 2023 P1, N=20, Not yet recruiting,
- |||||||||| JNJ-9530 / J&J
Enrollment open, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov) - Nov 18, 2023 P1, N=92, Recruiting, Trial completion date: Apr 2027 --> Oct 2027 Not yet recruiting --> Recruiting | Phase classification: P1b --> P1 | N=52 --> 92 | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: May 2026 --> Apr 2027
- |||||||||| prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment change, Trial completion date: A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 18, 2023 P1, N=92, Recruiting, Not yet recruiting --> Recruiting | Phase classification: P1b --> P1 | N=52 --> 92 | Trial completion date: Nov 2026 --> May 2027 | Trial primary completion date: May 2026 --> Apr 2027 N=52 --> 92 | Trial completion date: Oct 2027 --> Apr 2027
- |||||||||| C-TIL051 / AbelZeta Pharma
Trial initiation date, Metastases: C-TIL051 in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 15, 2023 P1, N=20, Not yet recruiting, Intranasal administration of ahaMSCs-Exos was safe and well tolerated, and a dose of at least 4 Initiation date: Mar 2023 --> Dec 2023
- |||||||||| prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment change, Trial completion date, Trial primary completion date: A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 13, 2023 P1, N=52, Recruiting, Initiation date: Mar 2023 --> Dec 2023 N=15 --> 52 | Trial completion date: Jul 2038 --> Oct 2027 | Trial primary completion date: May 2025 --> May 2026
- |||||||||| JNJ-9530 / J&J
Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) (clinicaltrials.gov) - Jul 12, 2023 P1, N=52, Not yet recruiting, Unknown status --> Completed N=15 --> 52 | Trial completion date: Oct 2025 --> May 2026 | Initiation date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2025 --> May 2026
- |||||||||| prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma (clinicaltrials.gov) - May 31, 2023 P1, N=7, Active, not recruiting, N=15 --> 52 | Trial completion date: Oct 2025 --> May 2026 | Initiation date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2025 --> May 2026 Recruiting --> Active, not recruiting | N=10 --> 7 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Jul 2023
- |||||||||| prizloncabtagene autoleucel (JNJ-4496) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects (clinicaltrials.gov) - May 26, 2023 P1, N=25, Active, not recruiting, Recruiting --> Active, not recruiting | N=10 --> 7 | Trial completion date: Oct 2022 --> Dec 2023 | Trial primary completion date: Jul 2022 --> Jul 2023 Recruiting --> Active, not recruiting | Trial completion date: Aug 2021 --> Dec 2023 | Trial primary completion date: Aug 2021 --> Jun 2023
|